Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 2/20 | 0.46 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.41 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RBP4 | P02753 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15537089 | 0.90 | FPR2 (0.56) | FPR2PROKR1KDM4EEPHX2ENPP2 | |
| SCHEMBL4223748 | 0.86 | CYP2D6 (0.46) | KDM4EALDH1A1CYP46A1MEN1KMT2A | |
| SCHEMBL3931364 | 0.85 | ANO1 (0.44) | FPR2PROKR1KDM4EALDH1A1MAPK1 | |
| SCHEMBL1094025 | 0.79 | KDM4E (0.54) | KDM4EALDH1A1MAPK1TDP1FFAR4 | |
| SCHEMBL15536965 | 0.79 | FPR2 (0.53) | FPR2PROKR1EPHX2ENPP2ALDH1A1 | |
| SCHEMBL15537181 | 0.77 | FPR2 (0.55) | FPR2PROKR1KDM4EEPHX2ALDH1A1 | |
| SCHEMBL16657604 | 0.76 | FPR2 (0.52) | FPR2PROKR1KDM4EEPHX2ALDH1A1 | |
| SCHEMBL30027758 | 0.76 | FPR2 (0.52) | FPR2PROKR1KDM4EEPHX2ALDH1A1 | |
| SCHEMBL15537084 | 0.74 | EPHX2 (0.53) | FPR2PROKR1EPHX2ALDH1A1CYP46A1 | |
| SCHEMBL28123147 | 0.72 | ALDH1A1 (0.52) | EPHX2ALDH1A1MAPK1RAB9ACYP46A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2069355-A1 | NOVEL TRICYCLIC SPIROPIPERIDINE COMPOUNDS, THEIR SYNTHESIS AND THEIR USES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2009-06-17 | — | — | EP | claimed |
| WO-2009011653-A1 | A PROCESS FOR THE PREPARATION OF INTERMEDIATES AND THEIR US IN THE SYNTHESIS OF SPIROPIPERIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | WO | claimed |
| US-20080167332-A1 | Novel Compounds 243 | ASTRAZENECA AB (SE) | 2008-07-10 | — | — | US | claimed |
| WO-2008010765-A1 | NOVEL TRICYCLIC SPIROPIPERIDINE COMPOUNDS, THEIR SYNTHESIS AND THEIR USES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2008-01-24 | — | — | WO | claimed |
| US-20090176815-A1 | Novel Tricyclic Spiropiperidine Compounds, Their Synthesis and Their Uses as Modulators of Chemokine Receptor Activity | ASTRAZENECA AB (SE) | 2009-07-09 | — | — | US | disclosed |
| EP-2069355-A1 | NOVEL TRICYCLIC SPIROPIPERIDINE COMPOUNDS, THEIR SYNTHESIS AND THEIR USES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2009-06-17 | — | — | EP | disclosed |
| WO-2009011653-A1 | A PROCESS FOR THE PREPARATION OF INTERMEDIATES AND THEIR US IN THE SYNTHESIS OF SPIROPIPERIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | WO | disclosed |
| US-20080167332-A1 | Novel Compounds 243 | ASTRAZENECA AB (SE) | 2008-07-10 | — | — | US | disclosed |
| WO-2008010765-A1 | NOVEL TRICYCLIC SPIROPIPERIDINE COMPOUNDS, THEIR SYNTHESIS AND THEIR USES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167332-A1 | Novel Compounds 243 | UGT1A10, ABCG2, VKORC1L1 | FPR2 2183/4885PROKR1 753/4885KDM4E 2805/4885 |
| US-20090176815-A1 | Novel Tricyclic Spiropiperidine Compounds, Their Synthesis and Their Uses as Modulators of Chemokine Receptor Activity | ACKR3, CCR2, CCR5 | FPR2 1224/4885PROKR1 35/4885KDM4E 4622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.